Objective: To examine the essential and potentially inappropriate use of antipsychotics across income groups.
Abbreviations

Clinical Implications
• Low-income people with schizophrenia are less likely to receive antipsychotic therapy and may need more active forms of support to encourage treatment.
• Seniors in long-term care and low-income seniors in the community have increased risk of potentially inappropriate antipsychotic treatment.
Limitations
• Our study used prescription fill data, which may overestimate actual medicine use and underestimate the number of prescriptions issued.
• Case ascertainment for schizophrenia, BD, and dementia were performed using administrative data.
T he discovery of the first antipsychotic, chlorpromazine, in the middle of the 20th century, marked an important milestone in the treatment of severe mental disorders. This class of medicines helped thousands of people with schizophrenia to manage the disorder's symptoms and improve their overall quality of life-so much so that 3 of these drugs (chlorpromazine, fluphenazine, and haloperidol) have been added to the WHO's Model Lists of Essential Medicines. 1 Newer antipsychotics have also been developed and are specified in current clinical practice guidelines as mainstay treatments for schizophrenia. 2, 3 While antipsychotics are deemed essential for the treatment of schizophrenic disorders, their use has expanded beyond this indication. 4 Several off-label uses of antipsychotics have been criticized for lack of supporting evidence and concerns about unnecessary exposure to risks. One example of potentially inappropriate use is the antipsychotic treatment of behavioural and psychological symptoms associated with dementia among seniors. Evidence from systematic reviews of high-quality studies indicates that antipsychotic treatment in these patients has limited efficacy and could increase the risks of cardiovascular events, weight gain, or death. [5] [6] [7] [8] Numerous warnings from manufacturers and regulatory agencies were issued from 2002 to 2005, discouraging such use, which continued to increase in 2007, albeit, at a significantly slower rate. 9, 10 In our study, we examined income-related disparities in these 2 facets of antipsychotic use-essential, compared with potentially inappropriate, uses. The examination of disparities is important because they could indicate poorquality care and could result in further inequities in health outcomes. We also tested the effect of public drug coverage on observed income-related disparities as antipsychotics are provided at no cost to registered mental health clients, recipients of income assistance, and residents of long-term care facilities. We employed a retrospective analysis of linked health administrative health care data from BC.
Methods
We obtained de-identified administrative health care data from Population Data BC, a population-based data repository. Our observation period for prescription drug use was calendar year 2005; however, we extracted medical and hospital use data for 2004 and 2005 for the purpose of identifying indicators of specific clinical needs. Data access permissions were granted by the BCMOHS and the PharmaNet Stewardship Committee. Ethics review and approval were granted by the Behavioural Research Ethics Board of the University of BC.
Study Cohorts
Two mutually exclusive cohorts were defined to assess income-related differences in the use of antipsychotics: one cohort of adults for whom antipsychotic use could be deemed essential, and one cohort of seniors for whom antipsychotic use could be considered potentially inappropriate. We excluded people who resided in BC for less than 9 months during each observation year and those who resided in health service delivery areas that had a high proportion of non-fee-for-service claims. These exclusions were done to mitigate possible bias in case ascertainment and health status measurement-known issues in claims data analyses. 11 We also excluded all people with missing data on income and sex to ensure comparability of data.
Study Cohort for Analysis of Essential Antipsychotic Use. The first cohort included adults, aged 19 to 64 years, who had a recorded diagnosis of schizophrenia. This age range was used to maximize the chances of selecting people who had the disorder (schizophrenia is rare among seniors) 12 and Résultats : Chez les adultes, la prévalence de l'utilisation essentielle d'antipsychotiques était élevée (85 %), et les probabilités élevées d'utilisation étaient évidentes chez les personnes du groupe de revenu moyen. Chez les personnes âgées, la prévalence d'un traitement par antipsychotiques possiblement contrindiqué était de 23 %, la prévalence étant plus élevée dans les soins de longue durée (56 %) que dans la communauté (13 %). Aucunes différences liées au revenu n'ont été constatées dans les soins de longue durée; toutefois, dans la communauté, des probabilités d'utilisation plus élevées ont été observées chez les personnes âgées à faible revenu.
Conclusion : Les personnes de ménages à faible revenu ont des taux légèrement inférieurs d'utilisation essentielle d'antipsychotiques et sont plus susceptibles de recevoir un traitement par antipsychotiques possiblement contrindiqué. also to reduce the chances of confounding antipsychotic use for schizophrenia with use for other conditions (for example, dementia and behavioural disorders). The cut-off age of 19 years reflects the actual threshold in BC for adult health services and insurance coverage.
We searched for evidence of schizophrenia diagnoses from the physician and hospital diagnostic records using ICD-9 295 and ICD-10 F20 diagnostic codes. We used a 2-year observation period for identifying people with schizophrenia to ensure that people who were diagnosed and maybe had started on antipsychotics in 2004 were included, even if they did not have any schizophreniarelated physician visits or hospitalization in 2005. A previously validated procedure for ascertaining people with schizophrenia using administrative health care data was used for case ascertainment, based on identifying people who received at least 2 physician visits or at least 1 hospital stay where schizophrenia was listed as the most responsible diagnosis. 13 Study Cohort for Analysis of Potentially Inappropriate Antipsychotic Use. The second cohort was comprised of seniors (aged 65 years and older) who had records indicating the presence of dementia but not schizophrenia or BD. This cohort was restricted to seniors as this is the population most likely to have the highest prevalence of dementia 14 and the lowest prevalence of schizophrenic disorders. 12 Physician and hospital claims data were used to identify relevant diagnoses. All patients who had at least one recorded schizophrenia diagnosis in either 2004 or 2005 were excluded. In addition, patients with a recorded BD diagnosis (ICD-9 296 but not 296.2, 296.3, and 296.9; and ICD-10 F30 and F31) were excluded as antipsychotics are an approved and recommended adjunctive therapy for BDs with psychotic symptoms. 15 Finally, people who did not have in-or outpatient dementia-related diagnoses were excluded (ICD-9 294, 298, 331, and 348; and ICD-10 F00 to F03). 16 The Essential and Potentially Inappropriate Use of Antipsychotics Across Income Groups: An Analysis of Linked Administrative Data
Study Variables
Antipsychotic Use. Our primary outcome measure was a dichotomous variable indicating whether people filled one or more prescriptions for antipsychotics in 2005. Prescription data were obtained from PharmaNet, a centralized database that records every prescription filled in community pharmacies throughout BC, regardless of patient age or insurance status (except for about 4% of the population who are covered by federal drug plans; that is, veterans, registered status Indians, federal penitentiary inmates, and members of the Royal Canadian Mounted Police). All prescriptions filled for antipsychotics were identified using the third level of the WHO-Anatomical Therapeutic Chemical classification system (that is, N05Axx; excluding lithium). 17 To examine long-term use, additional variables were constructed based on the accumulated number of days' supply. In the analysis of essential antipsychotic use, a dichotomous measure indicating more than 180 days' supply was used. For potentially inappropriate use, a variable based on a 90-day period was derived based on reports that antipsychotic treatment for dementia beyond this period is usually not accompanied by appreciable clinical benefits and also significantly increases risks of adverse events. 18 Income and Other Covariates. Our primary independent variable was income quintile, which was derived from 2 income data sources for 2005. The BCMOHS maintains household-level income data (verified by the Canada Revenue Agency) for all people who are registered with the income-based public drug benefit program in BC. Average incomes from tax returns filed by households residing in each Census Dissemination Area (the smallest census unit defined by Statistics Canada, with populations of about 400 to 700) are also available for all residents of BC. For the 83% of people included in our study, income quintiles were derived from household-level income information; income quintiles for the rest were based on neighbourhood-level income data. These income data were constructed with the assistance of Population Data BC and the BCMOHS and have been shown to be superior to area-based income data alone. 19 Indicator variables for public drug coverage were created based on flags from prescription claims data. In BC, filled antipsychotic prescriptions are assigned codes, depending on whether the prescription is for a long-term care resident, income assistance recipient, registered mental health client, or a person covered by the income-based plan, which applies to most BC residents.
As a crude measure of schizophrenia severity, we derived a dichotomous variable indicating whether a patient was hospitalized in 2004 or 2005, with schizophrenia as the most responsible diagnosis. This variable was included in the analysis of essential antipsychotic use to control for possible bias arising from the uneven distribution of people with severe schizophrenia across income strata.
We controlled for overall health status by counting ADGs based on the Johns Hopkins Adjusted Clinical Groups Case-Mix system. ADGs are groupings of diagnostic codes that are similar in severity and chronicity. A higher count of ADGs is generally indicative of greater overall clinical complexity and increased likelihood of health service use (including the use of prescription medications). 20 The other covariates included in the analyses were sex, age (5-year bands), and residence (in urban or nonurban areas)-all derived from the provincial health plan registry data.
Analysis
We performed multivariable logistic regression analyses to examine income-related disparities in the use of one or more antipsychotics (yes or no) and also in the long-term use of antipsychotics (yes or no). These regression models accounted for differences in the use of antipsychotics by age, sex, health status, schizophrenia hospitalization (for essential use analysis only), and place of residence. The selection of explanatory variables and other covariates included in the models were informed by the framework of health service use of Andersen and Newman, 21 which specifies 3 broad categories of factors that influence individual health service use: predisposing characteristics (sex and age), enabling resources (income and urban residence), and need characteristics (health status, and psychiatric and dementia diagnoses). As the main objective of our study was to examine income-related differences in antipsychotic use that are not due to other factors, all variables were simultaneously entered in the full logistic regression model.
In all of the logistic regression models, the highest income quintile, with an odds ratio equal to one, was used as the reference group. Odds ratios for income groups that have confidence intervals not containing the value of one were regarded as different from the reference group.
The contribution of targeted public drug coverage on observed income-related differences in antipsychotic use was assessed by including in the models a variable that indicates whether people were covered by patient-specific drug plans (that is, income assistance, mental health, or long-term care). Any notable changes in the direction or magnitude of the observed odds ratios were regarded as evidence of targeted public coverage's contribution to the observed income-related disparities. We did not control for targeted public coverage in the analysis of antipsychotic use among seniors in long-term care because prescription drug use for all such people is publicly covered by virtue of their being residents in long-term care facilities.
All statistical analyses were performed using Stata 10.1. 22
Results
Essential Antipsychotic Use
A total of 11 417 adults, aged 19 to 64 years, met the inclusion criteria of a recorded schizophrenia diagnosis in 2004 or 2005. People included in this cohort were predominantly men (60%), likely to live in urban areas (84%), and had an average of about 5 chronic conditions. More than a quarter had been hospitalized (27%), with schizophrenia as the most responsible diagnosis ( Table 1 ).
The prevalence of essential (85%) and long-term (more than 180 days) antipsychotic use (71%) were high in this population. The majority have used at least one newer antipsychotic (75%), while 10% appeared to have been exclusively treated with older antipsychotics. People in the third quintile had the highest prevalence of medication use, and this trend was observed both for essential and longterm antipsychotic use.
Results from the adjusted regression model indicated an inverted-U-shaped relation between income and odds of essential antipsychotic use. People in the lowest-income group (OR 1.05; 95% CI 0.90 to 1.23) had about the same odds of essential use as those in the highest-income group. The other income groups had slightly greater odds of use, with those in the third quintile (OR 1.71; 95% CI 1.44 to The Essential and Potentially Inappropriate Use of Antipsychotics Across Income Groups: An Analysis of Linked Administrative Data 2.04) having the highest odds of essential use. A similar pattern was observed for long-term use ( Table 2) .
Potentially Inappropriate Antipsychotic Use in Seniors With Dementia
A total of 33 633 seniors, aged 65 years and older, met the inclusion criteria of a recorded dementia, but not a schizophrenia or BD, diagnosis in 2004 or 2005. People included in this cohort were predominantly women (60%), likely to live in urban areas (82%), and had an average of about 7 chronic conditions. Around 23% of seniors were in long-term care facilities, and many of these long-term care residents were in the lower-income groups ( Table 3) .
Nearly 1 in 4 seniors (23%) who had a recorded dementia, but not a schizophrenia or BD, diagnosis may have received potentially inappropriate antipsychotic treatment, and about 1 out of 7 of these seniors (14%) may have been maintained on this regimen for more than 90 days (long-term use). Far more of the seniors with a recorded dementia, but not a schizophrenia or BD, diagnosis received at least one newer antipsychotic (20%) than older antipsychotics exclusively (2.5%). Lower-income seniors with recorded dementia, but not schizophrenia or BD, appeared to have higher levels and longer duration of potentially inappropriate antipsychotic use when compared with those with higher incomes (Table 3 ).
In long-term care facilities, almost 3 out of every 5 (56%) seniors with dementia, but not schizophrenia or BD, received potentially inappropriate antipsychotic treatment (data not shown). In comparison, only 13% of community-dwelling seniors with recorded dementia, but not schizophrenia or BD, received similar treatment (data not shown). Even after accounting for differences in age, sex, health status, and residence in urban areas, seniors in long-term care with recorded dementia, but not schizophrenia or BD, still had higher odds of receiving potentially inappropriate antipsychotic treatment (OR 9.31; 95% CI 8.75 to 9.91) when compared with their communitydwelling counterparts.
As there were significant differences in the prevalence of use between long-term care and community-dwelling seniors, 2 separate logistic regression analyses were performed in each subgroup. Among community-dwelling seniors with recorded dementia, but not schizophrenia or BD, we found that those from the lowest-income quintile had higher odds of potentially inappropriate use, compared with highestincome seniors (OR 1.24; 95% CI 1.10 to 1.39). Among seniors in long-term care with recorded dementia, but not schizophrenia or BD, no significant income-related differences were observed, suggesting that the risk of potentially inappropriate treatment is more or less the same, regardless of income levels. Similar patterns were observed with long-term antipsychotic use (Table 4 ).
Targeted Public Drug Coverage and Income-Related Disparities
A pattern indicative of an inequity in the essential use of antipsychotics was found when targeted public coverage was controlled for in the model. This suggests that lowerincome people, compared with higher-income people, have substantially lower odds of essential antipsychotic 
Discussion
Our study, which examined income-related differences in the use of antipsychotics, found that people in the lowerincome groups were less likely to receive essential, but more likely to receive potentially inappropriate, antipsychotic treatment. Further, our study results suggest that targeted public coverage may have not only encouraged essential use but also contributed, in part, to the observed high prevalence of potentially inappropriate antipsychotic treatment.
The inverted-U-shaped relation found between income levels and antipsychotic use appears to suggest that there are a few people who may not have benefited from the existing targeted public coverage. It could be that these people did not sign up, or were not eligible for coverage, or that more aggressive forms of support are needed to encourage antipsychotic use. However, this inequity does not diminish the protective effects of public coverage. Our results strongly suggest that inequities would be magnified without targeted public coverage. Similarly, the high prevalence of antipsychotic use found across all groups of people with schizophrenia seems to underscore the importance of targeted public coverage, which reduces financial barriers to accessing antipsychotic treatment among those with the disorder. Without targeted public coverage, our results suggest that these medications would not be used by as many people with schizophrenia as we found in this study.
The higher odds of potentially inappropriate antipsychotic use found among lower-income seniors with dementia living in the community appear to be similarly associated with targeted public coverage, which could have made antipsychotics more easily accessible to low-income seniors. This interpretation fits well with our finding that statistically significant differences in antipsychotic use attributable to income differences virtually disappeared when we accounted for variability in antipsychotic use owing to targeted public coverage.
The considerably higher prevalence of potentially inappropriate antipsychotic use found among seniors in the community, relative to seniors in long-term care, may also have been due, in part, to targeted public coverage. Antipsychotics, like any other prescription drugs, are provided, free of charge, to all seniors in long-term care facilities. In the community, seniors pay for their medications, except for those who are on income assistance or other patient-specific public drug coverage.
Alternatively, the higher prevalence of antipsychotic use in long-term care among seniors with dementia, but not schizophrenia or BD, may have something to do with the greater occurrence of challenging instances of agitation and aggression in residential facilities. 23 It has been argued that antipsychotic treatment may be used as a treatment of last resort in these extreme situations. 24, 25 Nonetheless, the extent to which use as a treatment of last resort explains the high prevalence of potentially inappropriate use we reported here is unknown and cannot be determined with the data available to us. Other evidence seems to suggest that antipsychotic use in long-term care is driven by considerations that are not in the best interest of the patients. For example, it has been shown that the chance of receiving antipsychotic therapy is strongly associated with staying in residential facilities that have high prescribing rates for antipsychotics, regardless of the clinical needs of the patients or the characteristics of the facility. 26 Our reported prevalence of antipsychotic use (56%) among long-term care residents is higher than the estimate recently released by the BCMOHS. 27 The difference in the estimates is primarily due to our calculation that counted only seniors with dementia, but not schizophrenia or BD, in the denominator. We also note that the government report found the prevalence of antipsychotic treatment among long-term care residents to have increased, from 37%, in the 1-year period of 2001-2002, to 50.3%, in the period covering April 2010 to June 2011. 27 Given this rising prevalence, our numbers (56%) are likely to be underestimates of the current prevalence of antipsychotic use among seniors with a dementia, but not a schizophrenia or BD, diagnosis in long-term care.
Some potential limitations of our study merit discussion. First, the outcome measure was based on the number of prescriptions filled-a variable that may overestimate actual use and also underestimate the number of prescriptions issued. Second, our study used administrative data to identify people with or without schizophrenia in 2004 and 2005. If some patients with schizophrenia did not use the health system during these years and were not appropriately coded in claims data, they may not have been included in our sample. 13 Third, our analysis of essential antipsychotic use may have been confounded by the uneven distribution of patients with severe schizophrenia across income groups. We have attempted to reduce this potential bias by incorporating a severity measure derived from hospitalization records. Lastly, it is possible that some seniors who actually had schizophrenia or BD may have been misclassified as not having these disorders. This bias is likely to be small as we have expanded our case ascertainment period to 2 years; restricted our cohort to a subpopulation where occurrence of the relevant disorders are rare; and, have excluded people who lived in areas with high rates of non-fee-for-service claims.
Conclusions
We found high prevalence of essential antipsychotic use among people with schizophrenia in BC, although income-related disparities in use persist and possibly affect people from the lowest-income groups. Our study has also provided some evidence for the potentially inappropriate use of antipsychotics, which affects mostly seniors in longterm care and some seniors from low-income households.
